<DOC>
	<DOC>NCT00631371</DOC>
	<brief_summary>Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.</brief_summary>
	<brief_title>Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC) Majority component of conventional clearcell type is mandatory At least 1 measurable lesion (per RECIST) Prior systemic treatment for RCC Evidence of current or prior central nervous system (CNS) metastases Cardiovascular disease Pregnant or nursing women Additional criteria applies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>temsirolimus</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>urogenital cancer</keyword>
</DOC>